Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Revolution Medicines, Inc. (Nasdaq: RVMD) enters the 44th Annual J.P. Morgan Healthcare Conference as a late-stage, pre-commercial oncology company focused on RAS(ON) inhibitors. The company’s FY24 results release (link) positions RVMD as “a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,” with a deep pipeline led by daraxonrasib, elironrasib and zoldonrasib.
Ocugen, Inc. (Nasdaq: OCGN) is a clinical-stage biotechnology company focused on gene therapies for blindness diseases and related ophthalmic biologics. Its core asset base is a “modifier gene therapy” platform built around nuclear hormone receptors (NHRs) designed to reset dysfunctional retinal gene networks rather than replace single mutated genes. The three flagship programs are OCU400 for retinitis pigmentosa (RP), OCU410 for geographic atrophy (GA, late-stage dry age-related macular degeneration) and OCU410ST for Stargardt disease, each targeting sizeable unmet-need populations in inherited and multifactorial retinal disease.
Cellectar Biosciences (Nasdaq: CLRB) is a late-stage clinical radiopharmaceutical company built around a proprietary phospholipid drug conjugate (PDC) platform. Its lead asset, iopofosine I 131, delivers radioactive iodine-131 directly to tumor cell membranes; the most advanced program is in relapsed/refractory Waldenström macroglobulinemia (WM) after BTK inhibitor therapy, supported by the pivotal CLOVER-WaM Phase 2 data described in the company’s Form 10-K 2024 (Business section).
Datavault AI Inc. (Nasdaq: DVLT) is a small/micro-cap technology company that wants to sit at the intersection of AI, Web3 and data monetization. It licenses a portfolio of patents and software platforms to tokenize and value “real-world assets” (RWA) – from genomic data and prescription flows to commodities and luxury goods – and still carries the legacy wireless-audio business acquired from WiSA.
On 9 January 2026, Aquestive Therapeutics announced that the US FDA had identified “deficiencies” in the NDA for Anaphylm (dibutepinephrine sublingual film). These deficiencies currently preclude discussions of labeling and post-marketing commitments.
A factual deep dive on where SAVA really stands after shutting down Alzheimer’s, pivoting to TSC-related epilepsy, facing a full FDA clinical hold, settling a $31.25M class action and attracting heavy call-option interest and insider buying.
HSV-1 gene therapy platform moves from skin to lung: robust CFTR expression in CF lungs, repeat dosing on deck, and JPM 2026 as the launchpad for a mutation-agnostic CF strategy.
SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day.
This is not a buy/sell note, but a way to show readers how Ondas (ONDS) has been covered on Merlintrader over the last months, how the stock moved from November into early January, and what the upcoming Needham Growth Conference presentation actually adds (or doesn’t add) to the picture. Educational only, not investment advice.
DA approval is in the bag, pricing is out in the open, and the call with transplant KOLs was basically a long “here’s how we want to own TA-TMA”. Let’s unpack what Omeros is really trying to do with YARTEMLEA, beyond the usual headline noise.
Micro-cap (~37M $) clinical/commercial biotech developing a targeted drug-device platform (TAMP + RenovoCath) for solid tumors, with a pivotal Phase 3 trial in locally advanced pancreatic cancer (TIGeR-PaC) and a near-term catalyst at ASCO GI 2026
KODK – Turnaround / Advanced Materials Deep Dive | Merlintrader trading Blog KODK (KODK) – TURNAROUND / ADVANCED MATERIALS & CHEMICALS Mid-cap industrial (≈$800M) in full transition: from legacy photography to commercial print, advanced materials & chemicals, EV battery electrodes…
After a brutal Phase 3 failure in diabetic macular edema (DME) and years of being treated as a write-off, Kodiak is back on catalyst watch thanks to strong GLOW1 data in diabetic retinopathy (DR), a fully enrolled confirmatory Phase 3 GLOW2 study and the ongoing DAYBREAK trial in wet AMD. All patients in GLOW2 are expected to complete their primary endpoint visit by the end of January 2026, with topline data guided for the first quarter of 2026. For a name that has historically moved violently on news, this is a critical “reboot or bust” window.
The slightly less polite, more cynical and more honest companion to the original Encyclopedia of Social Trader Myths. Same dark humour, more uncomfortable truths about how traders really behave on Stocktwits, Reddit, X and Discord.
Space and Data-as-a-Service micro-cap building a LizzieSat® small-sat constellation with on-orbit AI processing and a long-term partnership with NASA Stennis’ ASTRA programme. After three LizzieSats launched in 12 months and a fresh equity raise, SIDU has become one of the most watched small-sat names of early 2026.
On January 6, 2026, Bright Minds reported positive topline results from its open-label Phase 2 BREAKTHROUGH study of BMB-101 in adults with drug-resistant absence seizures and developmental and encephalopathic epilepsies (DEE)
Clinical-stage precision oncology small cap (~170–190M $) built around the AP3 predictive phosphoproteomics platform, advancing ACR-368 in registrational-intent Phase 2b (with planned confirmatory Phase 3) and ACR-2316, a dual WEE1/PKMYT1 inhibitor, with fresh data coming at the January 8, 2026 webcast
After years of being treated as a “show-me story”, Omeros enters 2026 with two key green lights: FDA approval of Yartemlea (narsoplimab-wuug) and a large strategic deal with Novo Nordisk on OMS906. This report walks through the approval process, current US/EU regulatory status, the financial impact of the Novo deal, and a catalyst map for 2026.
Over the last 18–24 months, NRx Pharmaceuticals (NRXP) has built a storyline around NRX-100 (preservative-free IV ketamine) that many retail traders translated into a simple, crisp line: “PDUFA by year-end 2025.”
Ondas Holdings (ONDS) has extended its powerful run into early 2026, hitting new four-year highs and moving decisively into mid-cap territory. The next major test for the story is the OAS Investor Day 2026, where management will present the updated 2026 business plan and financial outlook. This update is a companion to the full deep dive available here: ONDS – Ondas Holdings Inc. (full report) .